Bank Of America Corp Mereo Biopharma Group PLC Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Bank Of America Corp holds 84,018 shares of MREO stock, worth $354,555. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,018

Previous 78,718 6.73%

Holding current value

$354,555

Previous $259,000 16.6%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.58 - $4.25 $13,674 - $22,525	5,300 Added 6.73%	84,018 $302,000
Q1 2024 May 15, 2024	BUY	$2.3 - $4.05 $180,416 - $317,690	78,442 Added 28421.01%	78,718 $259,000
Q4 2023 Feb 14, 2024	BUY	$1.19 - $2.42 $327 - $665	275 Added 27500.0%	276 $0
Q2 2023 Aug 14, 2023	SELL	$0.79 - $1.43 $16,733 - $30,290	-21,182 Reduced 100.0%	1 $0
Q1 2023 May 12, 2023	SELL	$0.71 - $1.22 $32,906 - $56,543	-46,347 Reduced 68.63%	21,183 $15,000
Q4 2022 Feb 10, 2023	BUY	$0.5 - $1.01 $17,402 - $35,153	34,805 Added 106.36%	67,530 $50,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.73 $28,005 - $59,084	-34,153 Reduced 51.07%	32,725 $28,000
Q2 2022 Aug 12, 2022	SELL	$0.33 - $1.69 $43,814 - $224,382	-132,771 Reduced 66.5%	66,878 $74,000
Q1 2022 May 16, 2022	BUY	$1.04 - $1.7 $133,501 - $218,223	128,367 Added 180.08%	199,649 $223,000
Q4 2021 Feb 08, 2022	BUY	$1.51 - $2.59 $45,967 - $78,844	30,442 Added 74.54%	71,282 $114,000
Q3 2021 Nov 15, 2021	SELL	$2.2 - $3.17 $29,904 - $43,089	-13,593 Reduced 24.97%	40,840 $99,000
Q2 2021 Sep 13, 2021	BUY	$2.94 - $4.08 $160,033 - $222,086	54,433 New	54,433 $173,000

Others Institutions Holding MREO

# of Institutions

Shares Held

102M

Call Options Held

121K

Put Options Held

208K

View Full List

About Mereo Biopharma Group plc

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $527M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

More about MREO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Mereo Biopharma Group PLC Transaction History